Rathbones Group PLC Has $9.32 Million Holdings in DexCom, Inc. $DXCM

Rathbones Group PLC lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 79.9% in the third quarter, Holdings Channel.com reports. The firm owned 138,523 shares of the medical device company’s stock after selling 551,828 shares during the period. Rathbones Group PLC’s holdings in DexCom were worth $9,321,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of DXCM. Norges Bank bought a new stake in shares of DexCom in the second quarter valued at about $453,279,000. Groupama Asset Managment grew its holdings in shares of DexCom by 79,043.1% during the second quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock worth $350,601,000 after buying an additional 4,011,438 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in DexCom by 106.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after buying an additional 3,410,858 shares during the last quarter. Marshall Wace LLP raised its position in DexCom by 260.7% in the 2nd quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock valued at $333,630,000 after buying an additional 2,762,504 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in DexCom by 82.1% in the 2nd quarter. Federated Hermes Inc. now owns 3,633,139 shares of the medical device company’s stock valued at $317,137,000 after acquiring an additional 1,638,407 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on DXCM shares. Wells Fargo & Company reduced their price target on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. Truist Financial reissued a “buy” rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Mizuho increased their target price on shares of DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, February 13th. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a research note on Monday, January 12th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $85.18.

DexCom Stock Down 3.7%

NASDAQ:DXCM opened at $68.10 on Monday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The firm has a market capitalization of $26.21 billion, a price-to-earnings ratio of 32.43, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The stock’s 50 day moving average price is $70.69 and its two-hundred day moving average price is $68.75.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the prior year, the firm posted $0.45 EPS. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. Equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.